Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
By Sriparna Roy April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live ...
Stocktwits on MSN
'Pharma Bro' Martin Shkreli defends Revolution Medicines' pancreatic cancer study data: 'Progress compounds'
Revolution said on Monday that its late-stage trial evaluating its experimental cancer drug daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma, who had been previously treated, ...
REDWOOD CITY, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ...
Pancreatic cancer remains one of the toughest cancers to treat, but Revolution Medicines has data from an early-stage study showing its experimental treatment helped patients live longer without their ...
The last time I spoke about Revolution Medicines (RVMD) it was with a Seeking Alpha article entitled "Revolution Medicines: ...
Revolution Medicines, Inc. ((RVMD)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results